OACC SEC filings, in plain English
Everything Oaktree III Life Sciences has filed with the SEC that we hold — 40 filings, newest first, 39 with a plain-English summary of what changed and why it matters. Every row links to the primary document on EDGAR, so you can check the source rather than trust us.
The feed
live EDGAR captureNew filings appear here within minutes of hitting EDGAR; summaries follow once the pipeline has read them.
What changed: A Schedule 13G beneficial ownership report (routine compliance exhibit) identifying Decagon Asset Management LLP and Benjamin John Durham as reporting holders for Oaktree III Life Sciences (OACC). The submitted excerpt contains no updates to SPAC mechanics. It reports no changes to the trust per share value ($10.69), no resolution or motion affecting the liquidation deadline (2026-10-25), no advancement in target identification or due diligence, no announcement of a redemption campaign, and no commentary on sponsor conduct or deal progress. Why it matters: Schedule 13G filings generally disclose institutional or major shareholder stakes at or above five percent beneficial ownership, which investors sometimes track to gauge capital alignment or potential influence over business combination timing. However, the header-only text provides zero quantitative data, states no amendment status, and omits Item 4 purpose-of-transaction disclosures. Because the document makes no claims about customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel, it contains no substantive near-term signals for redemption pacing, trust value trajectory, or deal execution probability. Subscribers should await full filings or subsequent amendments to determine whether Decagon or Mr. Durham accumulated or reduced positions, crossed or maintained regulatory thresholds, or signaled support for a specific merger timeline.(flagged for human review)
What changed: Schedule 13G — beneficial ownership report. Barclays PLC filed a Schedule 13G disclosing beneficial ownership of Oaktree III Life Sciences common stock. The provided excerpt does not state the percentage of shares held, whether the filing reflects a recent acquisition, disposition, or passive position, nor does it outline any voting arrangements or intended actions relative to the SPAC’s 2026-10-25 deadline, $10.69 trust value, extension procedures, or merger search timeline. Why it matters: A Schedule 13G identifies holders exceeding the five percent beneficial ownership threshold, which can signal institutional positioning relevant to redemption dynamics, extension referendums, and target identification during the SEARCHING phase. Barclays PLC did not advance claims regarding customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel, and did not disclose how its stake would interact with the $10.69 per-share trust balance, the 2026-10-25 termination date, or sponsor conduct.
What changed: Quarterly report on Form 10-Q for Oaktree Acquisition Corp. III Life Sciences, a SPAC still searching for a business combination target. Trust per-share redemption value rose to $10.69 from $10.50 at year-end, with the trust account totaling $205.3M. Net income for the six months was $3.0M, all from trust interest. The Company's cash outside trust fell to $1.18M, and it had a working capital deficit of $0.47M. A subsequent $250k withdrawal from trust for working capital occurred on July 21, 2026. No business combination announcement or extension vote has occurred. The deadline remains October 25, 2026, and the Company again notes substantial doubt about its ability to continue as a going concern if no deal is reached. Why it matters: Trust value increased, but deadline pressure is mounting with only ~2.5 months left. Cash outside trust is thin and the Company may need sponsor loans to continue operations. The continued absence of a target or extension vote increases the risk of liquidation. Investors should monitor for any shareholder meeting to extend the deadline or for a transaction announcement.
What changed vs 2026-05-13trust $203.4M → $205.3M +1%trust account, combination deadline, going-concern doubt +11 moved · 3 with no prior record of ours
- Trust account
- $203.4M$205.3M
- Combination deadline
- 2026-10-25 · unchanged
- Going-concern doubt
- stated · unchanged
- Redeemable shares
- 19.2M · unchanged
SpacBrain reads this as $1,866,579 was added to the trust between the two filings.
The clause “5 Prepaid expenses 80,258 113,275 Total current assets 1,259,928 1,548,240 Cash held in Trust Account 205,280,770 201,563,532 TOTAL ASSETS $ 206,540,698 $ 203,111,772 LIABILITIES, CLASS A ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION AND”…
The clause …“Company s plans to raise additional capital will be successful. The Company has until October 25, 2026, to consummate a business combination. If a business combination is not consummated by then, the Company may, however, elect to”…
The clause …“Such potential liquidity shortfall and mandatory liquidation condition raise substantial doubt about the Company s ability to continue as a going concern. These unaudited condensed financial statements do not include any adjustments”…
The clause “300,000,000 shares authorized; 583,981 shares issued and outstanding (excluding 19,199,029 shares subject to possible redemption) as of June 30, 2026 and December 31, 2025 58 58 Class B ordinary shares, $ 0.0001 par value; 30,000,000”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
What changed: Routine compliance exhibit: a Schedule 13G beneficial ownership report (filing identifier 0001688382-26-000017) identifying Fort Baker Capital Management LP, Steven Patrick Pigott, and Fort Baker Capital, LLC as reporting persons for OACC. Mechanics update: The filing registers new regulatory disclosure triggered by the named holders crossing the statutory threshold for mandatory public disclosure. The excerpt provides no amendment to the 2026-10-25 business combination deadline, no recalculation of the $10.69 per-share trust account, no announcement of deal progression or extension approval, and no statement regarding sponsor conduct or redemption window changes. Substance limited to: the reporting entities’ assertion that they collectively control equity stakes triggering the 13G filing obligation, with no additional operational, financial, or strategic disclosures included in the provided text. Why it matters: Investor implication: As disclosed by the filing itself, this entry adds institutional or affiliated shareholders to the capitalization structure while Oaktree III Life Sciences remains in SEARCHING status. Because the text omits exact share quantities, acquisition dates, purchase prices, and the specific exemption claimed (passive versus activist), the document cannot be used to adjust redemption probability models, forecast trust distributions at the stated $10.69, or assess sponsor alignment relative to the 2026-10-25 deadline. Treating the reporters’ own claims of beneficial ownership at face value, this functions as a standard accumulation notice rather than a material catalyst affecting liquidation timelines or target pursuit.
What changed: Quarterly Report on Form 10-Q for the period ended March 31, 2026, filed by Oaktree Acquisition Corp. III Life Sciences, a blank-check company in search of a business combination. Trust account value increased from $201,563,532 (Dec 31, 2025) to $203,414,191 (Mar 31, 2026); redemption value per Class A share increased from $10.50 to $10.60. Net income for the quarter was $1,394,121 (vs $1,658,791 in prior year). Working capital deficit increased to $207,947. No business combination target has been selected. The company continues to have substantial doubt about its ability to continue as a going concern absent a business combination before the October 25, 2026 deadline. Why it matters: Trust per share continues to grow, but the company's cash burn and working capital deficit highlight the need for either a transaction or an extension soon. The going concern disclosure signals that failure to complete a deal by the deadline could lead to liquidation. No extension has been proposed yet, so shareholders should monitor progress.
What changed vs 2025-11-13trust $199.8M → $203.4M +2%trust account, combination deadline, going-concern doubt +11 moved · 3 with no prior record of ours
- Trust account
- $199.8M$203.4M
- Combination deadline
- 2026-10-25 · unchanged
- Going-concern doubt
- stated · unchanged
- Redeemable shares
- 19.2M · unchanged
SpacBrain reads this as $3,645,102 was added to the trust between the two filings.
The clause “Prepaid expenses 139,267 113,275 Total current assets 1,416,197 1,548,240 Cash held in Trust Account 203,414,191 201,563,532 TOTAL ASSETS $ 204,830,388 $ 203,111,772 LIABILITIES, CLASS A ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION AND”…
The clause …“Company s plans to raise additional capital will be successful. The Company has until October 25, 2026, to consummate a business combination. If a business combination is not consummated by then, the Company may, however, elect to”…
The clause …“Such potential liquidity shortfall and mandatory liquidation condition raise substantial doubt about the Company s ability to continue as a going concern. These unaudited condensed financial statements do not include any adjustments”…
The clause …“300,000,000 shares authorized; 583,981 issued and outstanding (excluding 19,199,029 shares subject to possible redemption) as of March 31, 2026 and December 31, 2025 58 58 Class B ordinary shares, $ 0.0001 par value; 30,000,000”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
What changed: Schedule 13G beneficial ownership report containing an attached Power of Attorney executed by The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC. The filing introduces no alterations to Oaktree III Life Sciences’ operational or redemption framework. Per the enclosed text, there are zero updates to trust valuations, shareholder approval thresholds, business combination timelines, or sponsor governance clauses. The submission solely updates internal corporate authorization for regulatory filings. Why it matters: For investors monitoring redemption deadlines, trust value preservation, extension votes, or target acquisition progress, this document offers no substantive shift. The entire Power of Attorney merely delegates signing authority for Securities Exchange Act of 1934 filings (specifically Rule 13f-1 or Regulation 13D-G) to the eighteen individuals named in the exhibit. According to the filing, this authorization remains valid until July 16, 2026, supersedes prior delegations dated July 29,2024 and October 1, 2024, and terminates automatically upon cessation of employment or function for any named individual. No assertions regarding target customer bases, projected revenues, addressable market sizing, technological roadmaps, strategic partnerships, active litigation, or executive personnel changes accompany the form, rendering it administratively inert for Merger Arbitrage or SPAC redemption tracking purposes.
What changed: Annual report on Form 10-K for the fiscal year ended December 31, 2025, filed by Oaktree Acquisition Corp. III Life Sciences, a blank-check company (SPAC) still searching for a target. No deal announced, no extension sought, no amendment to trust or charter. Trust value rose to $10.50 per share (from $10.08) due to interest income. Net income was $7.29 million, entirely from interest. The company reported $1.43 million in cash outside trust and working capital of $249k. The auditor's report again includes a going concern qualification due to the mandatory liquidation deadline of October 25, 2026. CEO Zaid Pardesi and board member David A. Berry were added as directors in January and October 2025 respectively. No redemptions occurred; all 19.2 million public shares remain outstanding and redeemable. Why it matters: The filing serves as a status update for a SPAC with 16 months left before mandatory liquidation. Trust value per share is $10.50, above the $10.00 IPO price, giving shareholders a cushion. The company's cash burn ($422k in operating cash flow) and thin working capital ($249k) raise liquidity risk. The ongoing going concern qualification signals the clock is ticking. New directors (Pardesi as CEO/board; Berry as independent director with biotech/SPAC experience) may indicate deal activity is being ramped up. No target is identified, but the language about a 'large backlog' of life sciences companies suggests the search continues. Investors tracking redemption risk should note the trust is fully intact and no shareholder vote has been called.
What changed vs 2025-03-27trust $193.6M → $201.6M +4%going concern APPEAREDtrust account, going-concern doubt, combination deadline +22 moved · 3 with no prior record of ours
- Trust account
- $193.6M$201.6M
- Going-concern doubt
- not statedstated
- Combination deadline
- not previously extracted2026-10-25
- Mandate language
- we intend to focus on industries that complement our managem… · unchanged
- Redeemable shares
- 19.2M · unchanged
SpacBrain reads this as $7,984,510 was added to the trust between the two filings.
The clause …“current assets 1,548,240 1,558,325 Long-term prepaid insurance 113,275 Cash held in Trust Account 201,563,532 193,579,022 TOTAL ASSETS 203,111,772 195,250,622 LIABILITIES, CLASS A ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION AND”…
SpacBrain reads this as the substantial-doubt sentence is in this filing and not in the previous one.
The clause …“accounting firm s report contains an explanatory paragraph that expresses substantial doubt about our ability to continue as a going concern. In connection with our assessment of going concern considerations under applicable”…
The clause …“in Note 1 to the financial statements, if the Company is unable to complete a business combination by October 25, 2026, the Company will cease all operations except for the purpose of liquidation. The mandatory liquidation date and”…
The clause …“300,000,000 shares authorized; 583,981 issued and outstanding (excluding 19,199,029 shares subject to possible redemption) as of December 31, 2025 and 2024 58 58 Class B ordinary shares, $ 0.0001 par value; 30,000,000 shares”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
What changed: A Schedule 13G/A amendment, classified as a routine regulatory compliance exhibit reporting changes in beneficial ownership. Barclays PLC filed the amendment to update its beneficial ownership disclosures. The provided excerpt attributes no specific share quantities, percentage thresholds, acquisition dates, or transaction prices to Barclays PLC. Consequently, the filing discloses nothing bearing on Oaktree III Life Sciences’ October 25, 2026 combination deadline, the reported $10.69 per share trust amount, redemption mechanics, extension voting processes, target deal progress, or sponsor conduct. Why it matters: The Schedule 13G/A format inherently tracks institutional position shifts that cross or adjust holdings relative to the five percent beneficial ownership reporting line. For investors tracking Oaktree III Life Sciences, Barclays PLC’s updated filing refreshes the known institutional register but carries no mechanical influence over redemption windows, trust maintenance, or business combination timelines. Beyond identifying the holder, the document contains zero statements regarding customers, revenue streams, market size, corporate strategy, proprietary technology, partnership arrangements, litigation exposure, or personnel rosters.
What changed: 10-Q (Quarterly Report). This filing is a routine quarterly report for the period ended September 30, 2025. It reports on the continuing search for a business combination target, financial results including net income of $1,966,742 for the quarter and $5,499,876 for the nine-month period, and trust account value growing to $199,769,089 (from $193,579,022 at year-end 2024) at a redemption value of $10.41 per share. The document discloses two subsequent events: On October 17, 2025, David A. Berry, MD, PhD, was appointed as an independent Class II director. On October 29, 2025, Thomas Sweeney resigned as CFO; George A. Martinez was appointed as the new CFO, effective immediately. The report reiterates a going concern qualification and pending deadline of October 25, 2026. Why it matters: The trust value per share has increased to $10.41 from $10.08, providing a growing floor for redemption. The CFO change is a material operational shift, but the resignation was stated as not due to disagreements with management. No business combination agreement has been announced and the deadline remains unchanged, reinforcing the time pressure on the sponsor.
What changed vs 2025-08-12trust $197.6M → $199.8M +1%going concern APPEAREDtrust account, going-concern doubt, combination deadline +12 moved · 2 with no prior record of ours
- Trust account
- $197.6M$199.8M
- Going-concern doubt
- not statedstated
- Combination deadline
- not previously extracted2026-10-25
- Redeemable shares
- 19.2M · unchanged
SpacBrain reads this as $2,192,321 was added to the trust between the two filings.
The clause …“current assets 1,480,874 1,558,325 Long-term prepaid insurance 113,275 Cash held in Trust Account 199,769,089 193,579,022 TOTAL ASSETS $ 201,249,963 $ 195,250,622 LIABILITIES, CLASS A ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION AND”…
SpacBrain reads this as the substantial-doubt sentence is in this filing and not in the previous one.
The clause “Such potential liquidity constraints and mandatory liquidation condition raise substantial doubt about the Company s ability to continue as a going concern. The condensed financial statements do not include any adjustments that might”…
The clause …“Company s plans to raise additional capital will be successful. The Company has until October 25, 2026, to consummate a Business Combination. If a Business Combination is not consummated by then, the Company may, however, elect to”…
The clause …“300,000,000 shares authorized; 583,981 issued and outstanding (excluding 19,199,029 shares subject to possible redemption) as of September 30, 2025 and December 31, 2024 58 58 Class B ordinary shares, $ 0.0001 par value; 30,000,000”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
What changed: A Form 8-K current report filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, specifically detailing an executive departure and appointment under Item 5.02. Chief Executive Officer Zaid Pardesi reported that Thomas Sweeney resigned as Chief Financial Officer effective October 29, 2025, to pursue other professional opportunities, and explicitly stated there were no disagreements with the Board or management. The Board simultaneously appointed George A. Martinez as the new Chief Financial Officer (principal accounting and principal financial officer) effective immediately. Mr. Pardesi attributed to the filing that Mr. Martinez currently serves as a Senior Vice President in Oaktree Capital Management, L.P.’s finance organization, previously worked at Ernst & Young from 2013 to 2024, holds California CPA licensure, and earned a Master of Accounting from the University of Southern California and a Bachelor of Arts from Occidental College. Mr. Pardesi disclosed that Mr. Martinez will receive zero compensation from the Company, has signed no employment agreement, and will execute indemnification and letter agreements on terms identical to those executed at the initial public offering. Why it matters: This filing makes no adjustments to the redemption calendar, trust account mechanics, or business combination deadline. The trust value per share remains $10.69, the warrant exercise price remains $11.50, and the liquidation deadline remains October 25, 2026. There is no announcement of a target, extension proposal, or change to shareholder voting rights. Regarding sponsor conduct, the appointment maintains administrative continuity through an existing Oaktree affiliate rather than hiring externally, which avoids dilution and preserves cash for potential deal expenses while the entity searches. For investors tracking the path to a de-SPAC transaction, this confirms governance stability but provides no progression toward a merger or adjustment to the redemption framework prior to the October 2026 deadline.
What changed: SEC Form 3, an initial statement of beneficial ownership that functions as a routine compliance exhibit. The filing discloses zero non-derivative transactions or equity holdings for Chief Financial Officer George Arthur Martinez. Consequently, there are no updates to the $10.69 per share trust value, the October 25, 2026 termination deadline, any active business combination, or sponsor trading conduct. Why it matters: A Form 3 with no reported public-equity positions indicates the executive currently holds no registrable shares or warrants from the IPO or promote that require disclosure in this filing. For investors monitoring redemption pressure, extension vote thresholds, or insider capital commitment, this submission confirms no new public-market accumulation or liquidation by senior leadership. The text contains no attributed claims regarding target search progress, revenue forecasts, technology licensing, customer contracts, partnership discussions, litigation, or material personnel changes. Without accompanying amendments or S-4/proxy filings, the document does not advance the SEARCHING phase nor alter the contractual mechanics governing shareholder redemptions or trust distribution schedules.
What changed: SEC Form 3 — insider ownership report. Director David A. Berry filed a routine Form 3 stating he reported no non-derivative transactions or holdings. No equity positions were acquired, disposed of, pledged, or established during the reporting window. The SPAC’s search parameters, board composition, and corporate governance mechanics remain static. Why it matters: This submission contains zero statements or data points regarding customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel changes beyond the director’s name. It is an administrative compliance record that indicates no alteration in sponsor conduct, insider alignment, or capital deployment. Investors tracking the redemption calendar, trust distribution schedule, extension windows, or merger negotiations should treat it as procedurally neutral; it conveys no actionable signal and requires no portfolio adjustment.
What changed: Form 8-K Current Report itemizing the appointment of a new independent director, committee placements, independence certifications, director compensation structure, and expected governance agreements. Per the Board of Directors of Oaktree Acquisition Corp. III Life Sciences, on October 17, 2025 the company appointed David A. Berry, MD, PhD, as a Class II independent director serving until a successor is qualified or he resigns/removes himself. The Board assigned Dr. Berry to the audit, nominating, and compensation committees and certified that he satisfies Nasdaq independence listing standards and the Rule 10A-3 definition of an independent director. The Board stated Dr. Berry will receive $0 in compensation for these director services. Consistent with disclosures in the Company’s Annual Report on Form 10-K filed March 27, 2025, the Board expects Dr. Berry to invest in a non-controlling minority position in Oaktree Acquisition Holdings III LS, LLC, matching arrangements for other independent directors. Dr. Berry is also expected to sign Letter Agreements and Indemnity Agreements on identical terms to those executed by directors and officers at the initial public offering. The filing confirms no family relationships exist between Dr. Berry and current management. The report was signed by Chief Executive Officer Zaid Pardesi. This filing leaves the stated $10.69 per-share trust value and the October 25, 2026 redemption deadline unchanged and does not trigger any extension vote, trust withdrawal, or redemption window adjustment. Why it matters: For shareholders monitoring a search-phase SPAC, this update refreshes board capacity without moving the redemption calendar or touching the trust account. Adding a director with extensive public-market operational experience across biotechnology and health-tech ventures (Valo Health, Omega Therapeutics, Seres Therapeutics, Axcella Health, Evelo Biosciences) and prior venture-stage roles at Flagship Pioneering and Averin Capital expands the board’s industry network ahead of the October 2026 deadline. The zero-compensation structure and standard indemnity/letter agreements keep governance expenses neutral, while the anticipated minority co-investment in the sponsor vehicle aligns independent directors with existing economics without encumbering the public trust. No target identification, LOI, merger discussion, or deal financing is reported, meaning the entity remains formally in search mode with the trust balance intact and redemption rights unaltered.
What changed: Quarterly report on Form 10-Q for the quarter ended June 30, 2025 (routine SEC compliance filing by a blank-check SPAC in searching status). The trust account value increased from $193,579,022 ($10.08 per share) at Dec 31, 2024 to $197,576,768 ($10.29 per share) at June 30, 2025, driven by $4,247,746 in interest income. Cash outside trust rose from $1,357,044 to $1,385,359. Working capital decreased from $831,002 to $441,907. The Company recorded net income of $3,533,134 for H1 2025. On June 3, 2025, CFO Courtney Conigliaro resigned and was replaced by Thomas Sweeney. No business combination target has been selected, and no extension has been proposed. The deferred underwriting fee remains $6,719,660 and deferred legal fees $299,088. The sponsor forfeited 231,492 founder shares upon the partial over-allotment exercise in October 2024, leaving 4,799,758 Class B shares outstanding. Why it matters: The trust value per share has grown to $10.29, offering a modest premium over the $10.00 IPO trust for redeeming shareholders. The deadline is still October 25, 2026, leaving ample time to find a target. The CFO resignation is an administrative change but could signal a shift in deal-preparation focus. The lack of any announced target or letter of intent confirms the SPAC remains in early search stage. The Company has sufficient liquidity ($1.4M cash plus $250k annual trust withdrawals) to continue operations without additional financing before a business combination.
What changed vs 2025-05-14trust $195.7M → $197.6M +1%trust account, redeemable shares1 moved · 1 with no prior record of ours
- Trust account
- $195.7M$197.6M
- Redeemable shares
- 19.2M · unchanged
SpacBrain reads this as $1,894,153 was added to the trust between the two filings.
The clause …“assets 1,561,142 1,558,325 Long-term prepaid insurance 37,758 113,275 Cash held in Trust Account 197,576,768 193,579,022 TOTAL ASSETS $ 199,175,668 $ 195,250,622 LIABILITIES, CLASS A ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION AND”…
The clause …“300,000,000 shares authorized; 583,981 issued and outstanding (excluding 19,199,029 shares subject to possible redemption) as of June 30, 2025 and December 31, 2024 58 58 Class B ordinary shares, $ 0.0001 par value; 30,000,000”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
What changed: A Schedule 13G/A amendment containing two appended Powers of Attorney executed by The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC. Both Goldman Sachs entities replaced prior Powers of Attorney dated July 29, 2024 and October 1, 2024 with new instruments executed on July 16, 2025. The updated documents revise the roster of designated attorneys-in-fact but preserve identical operative clauses: unilateral revocation rights, a July 16, 2026 expiration, New York governing law, and delegated authority to sign filings under Rule 13f-1 or Regulation 13D-G. These adjustments reflect routine internal staffing transitions and do not modify beneficial ownership percentages, voting directives, or investment discretion. Why it matters: The filing bears no relation to OACC’s merger timeline, redemption procedures, trust distribution mechanics, or sponsor governance protocols. It contains zero commercial assertions regarding target pipeline development, customer acquisition, revenue realization, market capitalization, technological milestones, strategic alliances, contingent liabilities, or executive turnover. All stated provisions are self-referential compliance delegations made exclusively by the two institutional holder entities listed on the form. Because the document discloses only administrative signing authority for periodic ownership reporting, it provides no signal regarding potential extension resolutions, tender offer scheduling, or deal conviction, and therefore holds no material relevance for transaction or liquidity tracking.
What changed: A Schedule 13G/A amendment comprising an Exhibit I Joint Filing Agreement confirming that Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander will file jointly on behalf of themselves regarding their beneficial ownership of Class A Ordinary Shares, par value $0.0001 per share, of Oaktree Acquisition Corp. III Life Sciences. The filing establishes a joint reporting arrangement under Rule 13d-1(k) of the Securities Exchange Act of 1934, executed on July 14, 2025, by Global General Counsel Gil Raviv for the two Millennium entities and personally by Israel A. Englander. Because the provided excerpt consists solely of the procedural joint agreement without a regulatory cover page, table of holdings, percentage of class, or transaction date, no numerical change in position or acquisition date is disclosed. Accordingly, the document reports no direct adjustment to the redemption calendar, trust distribution mechanics, or extension voting timeline. Why it matters: While institutional positioning typically warrants attention for a SPAC approaching its search deadline, this specific exhibit contains zero assertions regarding Oaktree’s operational strategy, technology, customer base, revenue, litigation, partnerships, or sponsor conduct. The only factual recitations—concerning corporate signatories, the governing statute, and the par value of the shares—are made by the named holders through their executed signatures. Investors tracking redemptions or business combinations will find this filing procedurally complete but substantively light until the accompanying Schedule 13G/A cover page discloses aggregate share quantities and the stated purpose of the holding.
What changed: A Form 3 initial statement of beneficial ownership of securities submitted to the SEC. Regarding the specified mechanical tracks, the filing reports zero non-derivative transactions or holdings for the named officer. It contains no provisions altering redemption windows, redistributing trust proceeds, voting on term extensions, advancing target acquisition due diligence, or restructuring sponsor promote allocations or lock-up periods. Why it matters: On any other substantive dimension, the exhibit contains no assertions about client relationships, earnings targets, total addressable markets, proprietary platforms, commercial alliances, active disputes, or hiring plans beyond the filer’s corporate title. Attributed entirely to the regulatory submission itself, the complete absence of recorded insider equity activity offers no verifiable datum on management capital commitment relative to public shareholder liquidity demands, thereby leaving trust yield assumptions and merger-timing expectations unanchored to insider positioning.
What changed: A Form 8-K current report filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, disclosing Item 5.02 events regarding officer departures, appointments, and compensatory arrangements. Mechanics Review: The filing contains no updates to the shareholder redemption window, trust account valuations, extension votes, merger discussions, or target acquisition status. Executive Changes: The board of directors accepted the resignation of Chief Financial Officer Courtney Conigliaro effective June 3, 2025. The registrant stated Ms. Conigliaro departed to pursue other professional opportunities and affirmed there were no disagreements with the board or management triggering the exit. The board simultaneously appointed Thomas Sweeney as the new Chief Financial Officer and principal accounting and financial officer, effective immediately. Sponsor Conduct & Compensation: Mr. Sweeney currently serves as a Managing Director in Oaktree Capital Management, L.P.'s finance organization and acts as Controller and Assistant Treasurer for Oaktree's business development companies. The board directed that he will not be compensated by the Company for his CFO duties, will sign no employment agreement, and will instead execute indemnity and letter agreements matching the terms issued to directors and officers during the Company's initial public offering in October 2024. No family relationships exist between Mr. Sweeney and existing directors or executives. Additional Governance: The board confirmed Alvin Shih as chair of the audit committee. Security Terms & Signatures: The registrant listed units consisting of one Class A ordinary share at $0.0001 par value and one-fifth of a redeemable warrant, alongside Class A ordinary shares and redeemable warrants, with each whole warrant exercisable for one Class A share at an exercise price of $11.50. Chief Executive Officer Zaid Pardesi executed the report on June 6, 2025. Why it matters: SPAC officer turnover often signals internal readiness for reporting obligations tied to a future combination, but this filing frames the transition as routine sponsorship-aligned succession rather than strategic disruption, particularly because the incoming CFO receives zero personal compensation and relies on standard pre-existing indemnification frameworks. The immediate internal replacement and audit committee chair confirmation suggest governance continuity is being maintained ahead of any potential due diligence or proxy solicitation cycle. Because no merger agreement, target identification, trust drawdown, extension proposal, or shareholder voting notice accompanies this submission, the existing fiduciary timeline and redemption mechanics proceed unadjusted. Investors monitoring whether management intends to seek an extension, renegotiate warrant structures, or accelerate a business combination should monitor subsequent filings, as this submission functionally serves as an administrative continuity record rather than a transactional catalyst.
What changed: Quarterly report on Form 10-Q for the quarter ended March 31, 2025. No new material changes. The trust account value increased by the accretion of the class A ordinary shares to the redemption value, reflecting interest earned. No business combination announced. Working capital burn was $75,561. The sponsor incurred $75,000 in administrative services fees, which became due to the related party during the period and is accrued. Why it matters: The filing confirms the SPAC remains in its searching phase with 15 months left before its deadline. The trust value per share grew from $10.08 to $10.19, providing a modest buffer above the IPO price for redeeming shareholders. The low cash burn and nominal operating expenses suggest the sponsor is not under liquidity pressure. No extension, no target, and no changes to the warrant structure or sponsor lock-up terms were disclosed.
What changed: Routine compliance exhibit — a Schedule 13G/A beneficial ownership report filed by the Healthcare of Ontario Pension Plan Trust Fund. The provided excerpt contains only the SEC form designation and the reporting entity’s name; it discloses no amended share quantities, percentage thresholds crossed, acquisition dates, or transaction purposes that would quantify a shift in institutional position. Why it matters: The Healthcare of Ontario Pension Plan Trust Fund’s submission does not modify OACC’s redemption calendar, announce a business combination, propose a trust extension, or comment on sponsor conduct relative to the October 25, 2026 deadline. The filing leaves the documented trust value of $10.69 per share unadjusted and introduces no revenue estimates, customer claims, market sizing, technology disclosures, strategic partnerships, personnel moves, or litigation updates. As a standard ownership amendment, it reflects passive registration or portfolio reconciliation rather than active deal acceleration; investors monitoring liquidity profiles, voting concentration, or capital deployment milestones should consult the complete exhibit for cumulative exposure and any conditional commitments tied to the search expiration.
What changed: Schedule 13G/A — a routine compliance exhibit amending a beneficial ownership disclosure. The filing text identifies three reporting holders—AQR Capital Management, LLC; AQR Capital Management Holdings, LLC; and AQR Arbitrage, LLC—but omits share quantities, percentage thresholds, transaction dates, and investment intent clauses. No details regarding OACC’s trust account, redemption calendar, extension mechanics, target search progress, or sponsor conduct are included in this excerpt. Why it matters: Amended 13G reports signal institutional portfolio rebalancing that can precede proxy voting on business combinations or trust dissolution. Monitoring whether the named AQR entities alter their positions helps investors anticipate potential institutional liquidity pressure or voting alignment ahead of shareholder decisions, though this excerpt does not quantify their stake or reveal any tactical stance toward redemptions or extensions.
What changed: Routine compliance exhibit: Schedule 13G beneficial ownership report filed by Barclays PLC. According to Barclays PLC, the entity reports beneficial ownership of OACC shares. The filing text discloses no share quantities, ownership percentages, acquisition dates, purchase prices, redemption mechanics, trust valuation, extension procedures, target search progress, or sponsor conduct updates. Why it matters: Per Barclays PLC, this filing satisfies periodic equity disclosure requirements. Because Barclays PLC’s submission contains no numerical data, timeline commitments, or strategic assertions, it does not alter Oaktree III Life Sciences’ SEARCHING status, shareholder redemption rights, trust composition, merger deadline expectations, or sponsor oversight. Material implications would require Barclays PLC to disclose specific position sizes, voting agreements, or intentions to influence corporate direction, none of which appear in the text.
What changed: A Schedule 13G filing accompanied by Exhibit 99 containing two Power of Attorney instruments executed by The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC. These administrative documents appoint fourteen named individuals per entity as attorneys-in-fact to execute and deliver Rule 13f-1 and Regulation 13D-G filings on behalf of the firms regarding securities deemed beneficially owned under the Securities Exchange Act of 1934. No adjustments affect Oaktree III Life Sciences’ redemption schedule, trust accounting, extension votes, merger negotiations, or sponsor conduct. The sole change is internal reporting authorization: The Group’s authority expires July 29, 2025 and supersedes a February 9, 2024 instrument. Goldman Sachs & Co.’s authority expires October 1, 2025 and supersedes a December 1, 2023 instrument. Both grant designated staff power to submit beneficial ownership reports, preserve unilateral revocation rights, terminate upon an attorney-in-fact’s departure, and default to New York law. They were countersigned on July 29, 2024 by Richard A. Friedman, Assistant Secretary for The Group, and on October 1, 2024 by Milton Millman, Managing Director for Goldman Sachs & Co., with the composite filing transmitted on 2025-05-09. Why it matters: The document discloses zero information regarding customers, revenue streams, addressable market size, corporate strategy, proprietary technology, channel partnerships, pending litigation, or executive leadership. Consequently, it provides no actionable signal for tracking deal progress, evaluating trust value retention, or anticipating liquidity events. The appointment of compliance personnel reflects routine institutional portfolio maintenance rather than strategic realignment or activist positioning. Investors monitoring SPAC mechanics should treat this as a procedural update for redemption calendars and capital account projections, while accepting the documented signatories and delegated reporting officers as verification of ongoing institutional oversight per the filing text.
What changed: Annual report on Form 10-K for the fiscal year ended December 31, 2024, filed by a blank check company (SPAC) that completed its IPO in October 2024 and is searching for a business combination target in the life sciences / healthcare sector. The SPAC completed its IPO in October 2024, raising $191,990,290 in the trust (net of deferred underwriting fees). As of December 31, 2024, the trust held $193,579,022, equating to $10.08 per public share (including interest earned). No business combination target has been selected. The company has 24 months from the IPO closing (October 2026) to consummate a deal. The filing confirms the trust per-share value, the redemption mechanics, and the sponsor's ownership structure. No extensions or amendments to the charter have been proposed. Why it matters: This is the first annual report post-IPO, providing audited financials, trust account details, and confirmation of the SPAC's status. Key metrics for investors: trust value $193.6M ($10.08/share), cash outside trust $1.357M, deadline October 2026. The filing also discloses the sponsor's substantial ownership (20% on an as-converted basis) and potential conflicts of interest. No change in redemption terms or extension requests. The document is material for tracking the SPAC's progress and financial position.
What changed: a routine compliance exhibit — Schedule 13G beneficial ownership report. the Healthcare of Ontario Pension Plan Trust Fund identifies itself as the reporting entity in the supplied excerpt, but the filing text provides no share quantities, acquisition dates, percentage thresholds, or transaction pricing. No modifications to the $10.69 trust value per share, the 2026-10-25 deadline, redemption mechanics, extension procedures, de-SPAC deal progress, or sponsor conduct are reported. Why it matters: a Schedule 13G generally signals an institutional investor has crossed or maintains a five-percent beneficial ownership stake, which affects voting power, public float, and governance oversight. because the excerpt lacks purpose statements, block identifiers, or amended filing markers, the holding alone does not confirm redemption timing shifts, extension vote implications, target selection activity, or any operational claims regarding customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel attributable to the Healthcare of Ontario Pension Plan Trust Fund.
What changed: A Schedule 13G (beneficial ownership report) identifying Oaktree-affiliated holding companies as listed holders relative to OACC. The filing excerpt discloses no share quantities, ownership percentages, transaction dates, purchase prices, or amendment flags. As reported, it contains no modification to the trust value per public share, the redemption calendar, the current SEARCHING designation, or verifiable sponsor conduct metrics. Why it matters: The SEC submission functions as a routine compliance exhibit confirming the continued regulatory registration of Oaktree capital-structure participants rather than signaling deal advancement or capital deployment. According to the provided text, the filing does not disclose financing sources, ownership thresholds, or a plan of arrangement. Consequently, it does not currently alter redemption calculus, trigger extension mechanisms, or indicate pivot activity toward a business combination target. Investors tracking the statutory deadline will require subsequent 13D/G/A filings, proxy materials, or merger-specific 8-K exhibits to verify whether sponsor equity has shifted, warrant structures have been activated, or tender offer parameters have been established.(flagged for human review)
What changed: A routine regulatory compliance exhibit (Form 8-K Current Report) disclosing a board resignation and subsequent leadership appointments. The company announced on January 6, 2025, that John Frank resigned from its board of directors. The filing attributes his departure to no disagreement over operations, policies, or practices. Concurrently, the company appointed existing director Aman Kumar as chairman and named Chief Executive Officer Zaid Pardesi as a Class III director serving until the third annual meeting. Citing the Final Prospectus filed October 24, 2024, the registrant restated that Pardesi and Kumar may hold material interests in Oaktree Acquisition Holdings III LS, LLC. Under the signature of Pardesi, the company certified that no undisclosed sponsor-related transactions exist under Regulation S-K Item 404(a), affirmed no family relationships link Pardesi to other directors or executives, and confirmed no prior arrangements dictated his board elevation. The document does not amend the October 25, 2026 liquidation deadline, reports no changes to the trust account balance per share, proposes no extension, and provides no data on target acquisition, customer contracts, revenue, market positioning, technology, partnerships, or legal proceedings. Why it matters: Board composition changes do not trigger adjustments to the redemption calendar, trust account distribution mechanics, or combination deadline. Centralizing governance authority within executive and board members who carry disclosed sponsor affiliations may accelerate alignment decisions if a business target emerges, but the filing confirms procedural continuity and stable capital structure protections through the unmodified October 25, 2026 expiry. Investors tracking redemption windows and sponsor conduct should monitor subsequent filings for any proposed extension votes or merger agreements that would activate the documented trust and voting frameworks.
What changed: A Form 8-K current report accompanied by a press release (Exhibit 99.1) announcing the administrative separate trading of securities following the initial public offering. The filing reports that commencing December 16, 2024, unit holders may elect to split their OACCU units into Class A ordinary shares (OACC) and warrants (OACCW). Separation requires shareholders to have brokers contact transfer agent Continental Stock Transfer & Trust Company. Each whole warrant is exercisable at $11.50, no fractional warrants will be issued, and unseparated units remain listed under OACCU. The SEC declared the related registration statement effective on October 23, 2024. These mechanics do not modify the stated $10.69 per share trust value, the 2026-10-25 business combination deadline, or the current SEARCHING status. Why it matters: Routine post-IPO unit separation expands secondary liquidity and allows independent trading of equity and leverage upside without triggering trust disbursements, voting requirements, or extension mechanisms. Beyond mechanics, the attached press release attributes background claims to the Company: it identifies Oaktree Capital Management L.P. as the sponsor, references past completed mergers with Hims & Hers and Alvotech, states that as of November 30, 2024 the sponsor has committed approximately $5 billion across 51 life sciences investments since 2013, describes a 12-person life sciences-dedicated investment team, reports Oaktree manages $205 billion in assets as of September 30, 2024, and notes the firm employs more than 1,200 people across 23 cities globally. Jefferies LLC, Citigroup Global Markets Inc., and UBS Investment Bank served as joint book-running managers. The document contains no target identification, financial projections, litigation updates, or changes to sponsor conduct.
What changed: Schedule 13G, a Securities Exchange Act of 1934 beneficial ownership report filed to disclose that investment advisers and holding companies have acquired greater-than-five-percent ownership of the issuer’s public securities. This filing does not alter Oaktree III Life Sciences’ redemption deadline, trust account balance per share, extension mechanics, target search timeline, or sponsor conduct. Per disclosures submitted by AQR Capital Management, LLC; AQR Capital Management Holdings, LLC; and AQR Arbitrage, LLC, executed by authorized signatory Henry Parkin on November 07, 2024 for an event date of October 31, 2024, each reporting entity beneficially owns 1,992,375 units representing Class A ordinary shares included as part of the units, holds sole voting and dispositive power over those 1,992,375 shares, and represents 10.07% of the class. The filers certify the securities were acquired and are held in the ordinary course of business and were not acquired or held to change or influence control of the issuer. The exhibit contains no claims regarding customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel. Why it matters: The disclosure anchors 1,992,375 shares (10.07% per filer) within a single investment management ecosystem, which concentrates float exposure and signals passive portfolio allocation rather than coordinated activism or redemption pressure. For investors tracking the stated $10.69 trust/share value and the October 25, 2026 liquidation window, AQR’s explicit 13G certification against influencing control provides no indication of future voting behavior at an extension vote or business combination meeting, leaving the SPAC’s SEARCHING status and contractual mechanics unmodified.
What changed: A Form 8-K Current Report filed by Oaktree Acquisition Corp. III Life Sciences to disclose the partial exercise of the underwriters' over-allotment option, a corresponding increase in private placement purchases by the sponsor, the resulting automatic forfeiture of founder shares, and an unaudited pro forma balance sheet. The company states that on October 30, 2024, underwriters purchased 1,699,029 additional public units at $10.00 per unit, generating $16,990,290 in gross proceeds, and forfeited the right to buy the remaining 925,971 units. Simultaneously, the sponsor bought 33,981 additional private placement units at $10.00 per unit for $339,810 in gross proceeds. Due to the partial exercise, the sponsor forfeited 231,492 Class B ordinary shares at no cost. The Company reports that cumulative trust proceeds rose to $191,990,290 as of October 30, 2024. No amendments to the October 25, 2026 redemption deadline or the SEARCHING status were disclosed. The unaudited pro forma balance sheet, prepared by management, reflects a deferred underwriting fee increase to $6,719,660, total current liabilities of $891,049, and an accumulated deficit of $(5,828,531) after writing off a $268,690 over-allotment liability and recording accretions. Why it matters: The filing provides the exact trust balance and revised capital structure required to update per-share redemption metrics and track sponsor equity dilution mechanisms ahead of the fixed liquidation date. The automatic share forfeiture demonstrates standard contractual alignment without triggering sponsor governance actions or search delays. Because the document is strictly a post-IPO capital transaction report, it contains no statements regarding acquisition targets, revenue projections, market sizing, technology roadmaps, strategic partnerships, or executive personnel changes. Management explicitly attributes the pro forma data to internal preparation, notes that the independent registered public accounting firm performed no audit, review, or assurance procedures, and warns investors not to rely on the figures as indicative of historical or future financial positions. The report neither advances nor impedes the target identification timeline.
What changed: Form 4 insider ownership report. The filing identifies itself as a FORM 4 insider ownership report. According to the transaction records dated 2024-10-30, ten affiliated reporting persons (Oaktree Acquisition Holdings III LS, LLC; Oaktree Acquisition Holdings III LS GP, Ltd.; OAKTREE CAPITAL MANAGEMENT LP; Oaktree Capital Management GP, LLC; Oaktree Capital Holdings, LLC; Oaktree Capital Group Holdings GP, LLC; Brookfield Asset Management Ltd.; BROOKFIELD Corp /ON/; Oaktree Capital Group Holdings, L.P.; and BAM Partners Trust) executed a conversion that resulted in acquiring 33,981 shares at $10 each. Following this acquisition, the group holds 583,981 shares. This update tracks sponsor and affiliate equity adjustments without altering the public redemption calendar, the stated $10.69 trust/share balance, or the 2026-10-25 liquidation deadline. Why it matters: The document makes no claims regarding business target search progress, merger negotiations, trust account activity, extensions, customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel. As the filing indicates, each listed entity identifies itself as a 10% owner within the submission framework, reflecting standard pre-deal capital structure maintenance rather than active deal negotiation or sponsor conduct shifts. Because the submission contains only routine insider share accounting that leaves the redemption timeline and deal trajectory untouched, it carries low immediate materiality for investors tracking SPAC mechanics.
What changed: A Current Report on Form 8-K announcing the consummation of an Initial Public Offering (IPO), a concurrent private placement, and the subsequent partial exercise of the underwriters' over-allotment option, accompanied by Exhibit 99.1 containing an audited balance sheet dated October 25, 2024, and extensive financial statement notes. Oaktree Acquisition Corp. III Life Sciences consummated its IPO on October 25, 2024, selling 17,500,000 public units at $10.00 per unit, depositing $175,000,000 into a trust account administered by Continental Stock Transfer & Trust Company. On October 30, 2024, the underwriters partially exercised their over-allotment option, purchasing 1,699,029 additional units at $10.00 for $16,990,290, while forfeiting the right to purchase the remaining 925,971 units. Concurrently, the sponsor, Oaktree Acquisition Holdings III LS, LLC, purchased 550,000 private placement units for $5,500,000 at closing, then acquired 33,981 additional units for $339,810 following the over-allotment closure. The sponsor originally obtained 5,031,250 founder shares for $25,000 on July 15, 2024, but forfeited 231,492 shares on October 30, 2024, due to the partial over-allotment exercise. Transaction costs amounted to $10,653,009, broken down into a $3,500,000 cash underwriting discount and $6,125,000 in deferred underwriting fees, with an additional approximately $594,661 in deferred fees added post-over-allotment. The filing formalizes a 24-month combination window running through the closing of the IPO, establishing a hard redemption and liquidation deadline. Trust mechanics dictate that interest may be withdrawn to fund working capital up to $250,000 annually (with unused amounts rolling over) or to pay taxes (explicitly excluding the 1% U.S. federal excise tax implemented by the Inflation Reduction Act of 2022). Upon liquidation, the company may deduct up to $100,000 of interest for dissolution expenses before distributing pro-rata trust balances to public shareholders. The sponsor has agreed to indemnify the company if third-party claims reduce trust assets below the lesser of $10.00 per share or the actual per-share trust value. The registrant also entered a $25,000 monthly administrative support agreement effective October 23, 2024, and notes that a $251,230 promissory note from the sponsor is now due on demand. Why it matters: This filing marks OACC's definitive shift from a pre-IPO blank check vehicle to a capitalized public shell, locking in the trust balance and underwriting fee structure that will directly impact net asset value and redemption economics. Management states that as of October 25, 2024, the company has not identified any business combination target and has conducted no substantive discussions toward a transaction. The stated acquisition strategy requires targets carrying an aggregate fair market value of at least 80% of the trust's net assets (excluding deferred underwriting commissions and taxes on interest) and necessitates obtaining 50% or more of the target's voting securities to satisfy the Investment Company Act of 1940 thresholds. The independent auditor, WithumSmith+Brown PC, issued an unqualified opinion on the October 25 balance sheet, confirming $2,000,000 in operating cash and $81,800 in prepaid expenses offset by $7,583,827 in total liabilities, leaving a shareholders' deficit of $5,502,027. Chief Executive Officer Zaid Pardesi executed the 8-K. Financial notes detail the derivative treatment of the over-allotment liability, valued at $268,690 via a Black-Scholes model using 4.89% volatility, and the allocation of $196,000 to public warrants priced using a Monte Carlo simulation applying 11.7% volatility and a 7.01-year term. Risk disclosures authored by the registrant warn that geopolitical instability from the Russia-Ukraine and Israel-Hamas conflicts could disrupt global capital markets, trigger supply chain interruptions, and hinder the search for viable life sciences targets. The filing attributes all strategic objectives, market outlooks, and procedural mechanics exclusively to management and contractual undertakings, with no operating revenues generated to date and future performance reliant solely on non-operating trust interest and eventual business combination execution.
What changed: Routine compliance exhibit (Schedule 13G under the Securities Exchange Act of 1934) filed pursuant to Rule 13d-1(c) disclosing beneficial ownership exceeding five percent of Oaktree Acquisition Corp. III Life Sciences Class A ordinary shares. According to the filing, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander report beneficial ownership of 916,743 shares, representing 5.1% of the class. All three reporting persons disclose shared voting power and shared dispositive power over 916,743 shares, with sole voting power and sole dispositive power recorded at zero. The signatories certify the securities were not acquired or held to influence control. The document notes that as of October 24, 2024, a CUSIP for the Class A ordinary shares is unavailable, while G6717R120 applies to the units. No updates to redemption deadlines, trust account mechanics, extension votes, merger negotiations, or sponsor conduct are contained herein. Why it matters: Positioning by the named entities establishes a substantial passive block without altering governance leverage, given the explicit shared-only authority and control certification. The absence of sole voting or dispositive rights reduces the likelihood of unilateral redemption pressure or trust restructuring demands. The administrative distinction between unit and Class A share CUSIP availability reflects standard settlement timeline synchronization rather than commercial developments. Because the filing contains no operational metrics, strategic declarations, customer commitments, revenue projections, market estimates, technology roadmaps, partnership frameworks, litigation exposures, or executive changes beyond legal signatory titles, investors must monitor subsequent proxy statements, merger definitive agreements, or trust indenture amendments for concrete combination timelines, special meeting schedules, or capital commitment adjustments.
What changed: This is a Form 8-K Current Report filed by Oaktree Acquisition Corp. III Life Sciences (the SPAC) reporting its initial public offering (IPO) and the entry into foundational agreements. The document contains the full text of the underwriting agreement, investment management trust agreement, warrant agreement, private placement purchase agreement, registration and shareholder rights agreement, letter agreement (insider letter), administrative services agreement, and a press release announcing the IPO pricing. The SPAC consummated its IPO of 17,500,000 units on October 25, 2024, raising gross proceeds of $175,000,000 (sold at $10.00 per unit). The trust was funded with the IPO proceeds and $5,500,000 from the Sponsor's purchase of 550,000 Private Placement Units. The company also adopted its Amended and Restated Memorandum and Articles of Association. These actions move the SPAC from pre-IPO to a funded, actively searching SPAC with a trust of $10.69 per share and a deadline of October 25, 2026. Why it matters: This filing establishes the SPAC's financial foundation for its search period. The trust has a per-share value of $10.69, providing a known redemption baseline for investors. The documents detail critical terms including lock-up periods (Founder Shares: 180 days post-business combination; Private Placement Units: 30 days post-business combination), an underwriting fee structure (including a deferred discount of $0.35/unit paid only upon a business combination from the trust), and that the Sponsor will indemnify the trust against certain third-party claims up to the $10.00 per share minimum. The trust assets can only be used post-deal or for permitted withdrawals (taxes and up to $250k/year in working capital from interest), preserving principal for shareholders.
What changed: Rule 424(b)(4) Prospectus filed pursuant to the Securities Act registering the initial public offering of 17,500,000 Units of Oaktree Acquisition Corp. III Life Sciences, a newly organized Cayman Islands blank check company. This filing establishes the foundational mechanics for shareholder redemptions, trust account administration, extension timelines, and sponsor conduct, while introducing the company’s strategic focus and leadership roster. Why it matters: Investors monitoring capital event timelines and trust preservation must recognize that the 15% redemption cap and the 24-to-36 month extension corridor define the maximum capital retention parameters before mandatory liquidation. The disclosed sponsor economics—founder shares issued at $0.005 per share, fixed monthly administrative withdrawals, and convertible debt structures—create measurable dilution vectors that will directly impact net tangible book value calculations and per-share liquidation thresholds during any future vote.
What changed: SEC Form 3 — insider ownership report filed by director Frank John for Oaktree Acquisition Corp. III Life Sciences. Per the filing, Frank John reported 'No non-derivative transactions or holdings.' There are no changes to insider equity positions, and the document contains no data regarding the SPAC’s $10.69 per share trust, the 2026-10-25 conversion deadline, extension mechanisms, target identification, or sponsor execution. No claims regarding customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel appear in the exhibit. Why it matters: Investors tracking redemption deadlines, trust value, extensions, deal progress, and sponsor conduct will note the lack of insider buying, selling, or warrant exercise that typically signals management conviction or capital allocation shifts. The report confirms routine regulatory compliance without updating the acquisition timeline or affecting shareholder economics. As a purely administrative holding statement, it provides no evidence of imminent deal activity or sponsor liquidity pressure, leaving the existing $10.69 trust value, search status, and 2026-10-25 deadline unchanged.
What changed: A Form 3 insider ownership report filed with the SEC to disclose initial security holdings for Oaktree Acquisition Corp. III Life Sciences. Per the Form 3 filing, reporting person and director Shih Alvin stated that he reported no non-derivative transactions or holdings. This disclosure creates no change in insider equity positions, has no impact on the SPAC’s SEARCHING status, and does not alter the redemption calendar, trust distribution mechanics, or extension procedures. Why it matters: While the report satisfies routine insider compliance requirements, it contains no substantive updates regarding deal progress, sponsor conduct, customer concentration, revenue forecasts, addressable market size, technological roadmap, commercial partnerships, active litigation, or leadership transitions. As noted in the filing, no material shifts occurred. Existing structural parameters remain static: the trust value is documented at $10.69 per share and the business combination deadline stands at 2026-10-25.
What changed: Form 3—Initial Statement of Beneficial Ownership. This Form 3, filed 2024-10-23 by director Paul M Meister, reports no non-derivative transactions or holdings. It leaves Oaktree III Life Sciences’ SEARCHING status, its $10.69 trust per share, and its 2026-10-25 deadline completely unchanged, with no disclosed business combination milestones, trust extension resolutions, or sponsor conduct modifications. Why it matters: The filing is a standard SEC Section 16(a) compliance submission that confirms zero insider equity accumulation or divestment during the pre-merger search phase. For investors tracking redemption pressure, trust account stability, or early insider conviction signals, the explicit absence of reported transactions indicates no immediate mechanical impact on the redemption calendar, warrant exercise thresholds, or sponsor alignment metrics.
What changed: A Securities and Exchange Commission Form 3 insider ownership report filed by Oaktree Acquisition Corp. III Life Sciences’ Chief Operating Officer, Mathew Pendo, explicitly stating that no non-derivative transactions or holdings were reported. The filing registers an initial Form 3 submission but records zero equity or derivative positions for the reported executive. There are no modifications to the redemption calendar, no impact on the stated trust value of $10.69 per public share, no adjustment to the October 25, 2026 business combination deadline, and no alterations to sponsor conduct or extension provisions. The document contains no claims regarding revenue, market size, technology, partnerships, litigation, or operational milestones beyond confirming the COO’s title. Why it matters: For investors tracking Oaktree III Life Sciences during its SEARCHING phase, this routine compliance exhibit confirms regulatory disclosure without shifting capital structure or deal momentum. The explicit absence of reported holdings indicates the COO has not yet committed personal capital to founder shares, warrants, or public units, leaving traditional sponsor alignment signals and trust liquidity static. Market participants awaiting a merger announcement, proxy material, or extension vote receive administrative confirmation rather than strategic or financial updates.
In plain English
Redemption deadlinethe last day to hand shares back for cash
Set by the filing that calls the meeting. Tender after it and the company is under no obligation to pay you the trust value.
Cash in trust / trust per sharethe cash the company is holding for each public share
Filed quarterly in the 10-Q's XBRL. It earns interest between filings, so the figure on a given day is slightly higher than the last filed one — where we show that we label it an estimate.
Accession numberthe SEC's unique id for one filing
Every figure on this page carries the accession of the filing that states it, so you can open the primary document rather than trust us.